Pentetate calcium trisodium Disease Interactions

The use of the nebulized radiomitigation chelators, pentetate zinc trisodium, and pentetate calcium trisodium is associated with asthma exacerbation. Caution is recommended when using these agents in asthmatic patients due to the risk for asthma exacerbations when these agents are administered by the inhalation route.

Pentetate calcium trisodium should be used only as a single dose in patients with hemochromatosis. Deaths have been reported in patients with severe hemochromatosis with the use of pentetate calcium trisodium by intramuscular injection for more than one day. Use pentetate calcium trisodium with caution in individuals with severe hemochromatosis.

Radiomitigation chelators such as pentetate zinc trisodium and pentetate calcium trisodium treatment may lead to depletion of body stores of endogenous metals. The risk for depletion increases when these agents are administered over several months. It is recommended to monitor serum zinc levels, electrolytes and blood cell counts during therapy. Care should be exercised in patients with electrolytes disorders or endogenous metals imbalance. Give mineral or vitamin plus mineral supplements as appropriate.

Radiomitigation chelators such as pentetate zinc trisodium and pentetate calcium trisodium are excreted by glomerular filtration. No dose adjustment is needed; however, care should be exercised when using these agents in patients with renal impairment as this condition may decrease their rates of elimination and increase the serum half-life. In heavily contaminated patients with renal impairment, high-efficiency high flux dialysis may be used to increase the rate of elimination. It is recommended to monitor serum creatinine, BUN, and urinalysis during therapy with these agents.